Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer - PubMed (original) (raw)
doi: 10.4161/cbt.8.11.8874. Epub 2009 Jun 29.
Affiliations
- PMID: 19502809
- DOI: 10.4161/cbt.8.11.8874
Free article
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer
Agnieszka K Witkiewicz et al. Cancer Biol Ther. 2009 Jun.
Free article
Abstract
Here, we determined the possible association of stromal caveolin-1 (Cav-1) levels with DCIS recurrence and/or progression to invasive breast cancer. An initial cohort of 78 DCIS patients with follow-up data was examined. As ER-positivity was associated with recurrence, we focused our analysis on this subset of 56 patients. In this group, we observed that DCIS progressed to invasive breast cancer in approximately 14% of the patient population (8/56), in accordance with an expected progression rate of 12-15%. Nearly ninety percent of DCIS patients (7/8) that underwent recurrence to invasive breast cancer had reduced or absent levels of stromal Cav-1. Remarkably, an absence of stromal Cav-1 (score = 0) was specifically associated with early disease progression to invasive breast cancer, with reduced time to recurrence and higher recurrence rate. All DCIS patients with an absence of stromal Cav-1 underwent some form of recurrence (5/5) and the majority (4/5) underwent progression to invasive breast cancer. This represents an overall cumulative incidence rate of 100% for recurrence and 80% for progression. An absence of stromal Cav-1 in DCIS lesions was also specifically associated with the presence of inflammatory cells. Conversely, ninety-seven percent of ER(+) DCIS patients (35/36) with high levels of stromal Cav-1 (score = 2) did not show any invasive recurrence over the duration of follow-up (4-208 mo), and 89% of such patients are estimated to remain free of invasive recurrence, even after 15 y. Thus, determination of stromal Cav-1 levels may be a useful new biomarker for guiding the treatment of ER(+) DCIS patients.
Similar articles
- An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, Kleer CG, Brody JR, Lisanti MP. Witkiewicz AK, et al. Am J Pathol. 2009 Jun;174(6):2023-34. doi: 10.2353/ajpath.2009.080873. Epub 2009 May 1. Am J Pathol. 2009. PMID: 19411448 Free PMC article. - Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM. El-Gendi SM, et al. Pathol Oncol Res. 2012 Apr;18(2):459-69. doi: 10.1007/s12253-011-9469-5. Epub 2011 Nov 7. Pathol Oncol Res. 2012. PMID: 22057638 - Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L. Van Bockstal M, et al. Histopathology. 2013 Oct;63(4):520-33. doi: 10.1111/his.12188. Epub 2013 Jul 26. Histopathology. 2013. PMID: 23889174 - 259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.
Di Saverio S, Catena F, Santini D, Ansaloni L, Fogacci T, Mignani S, Leone A, Gazzotti F, Gagliardi S, De Cataldis A, Taffurelli M. Di Saverio S, et al. Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review. - A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR, Agahozo MC, Koppert LB, van Deurzen CHM. Van Bockstal MR, et al. Int J Cancer. 2020 Mar 1;146(5):1189-1197. doi: 10.1002/ijc.32362. Epub 2019 May 8. Int J Cancer. 2020. PMID: 31018242 Free PMC article. Review.
Cited by
- Loss of caveolin-1 and gain of MCT4 expression in the tumor stroma: key events in the progression from an in situ to an invasive breast carcinoma.
Martins D, Beça FF, Sousa B, Baltazar F, Paredes J, Schmitt F. Martins D, et al. Cell Cycle. 2013 Aug 15;12(16):2684-90. doi: 10.4161/cc.25794. Epub 2013 Jul 29. Cell Cycle. 2013. PMID: 23907124 Free PMC article. - Breast tumour stroma is a prognostic indicator and target for therapy.
Howell A, Landberg G, Bergh J. Howell A, et al. Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S16. doi: 10.1186/bcr2435. Epub 2009 Dec 18. Breast Cancer Res. 2009. PMID: 20030867 Free PMC article. No abstract available. - Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling".
Pavlides S, Tsirigos A, Vera I, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F, Lisanti MP. Pavlides S, et al. Aging (Albany NY). 2010 Apr;2(4):185-99. doi: 10.18632/aging.100134. Aging (Albany NY). 2010. PMID: 20442453 Free PMC article. - Local outcomes in ductal carcinoma in situ based on patient and tumor characteristics.
Schnitt SJ. Schnitt SJ. J Natl Cancer Inst Monogr. 2010;2010(41):158-61. doi: 10.1093/jncimonographs/lgq031. J Natl Cancer Inst Monogr. 2010. PMID: 20956823 Free PMC article. Review. - Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis.
Castello-Cros R, Bonuccelli G, Molchansky A, Capozza F, Witkiewicz AK, Birbe RC, Howell A, Pestell RG, Whitaker-Menezes D, Sotgia F, Lisanti MP. Castello-Cros R, et al. Cell Cycle. 2011 Jun 15;10(12):2021-34. doi: 10.4161/cc.10.12.16002. Epub 2011 Jun 15. Cell Cycle. 2011. PMID: 21646868 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- R01-CA-120876/CA/NCI NIH HHS/United States
- R01-CA-70896/CA/NCI NIH HHS/United States
- R01-CA-098779/CA/NCI NIH HHS/United States
- R01-CA-86072/CA/NCI NIH HHS/United States
- R01-CA-75503/CA/NCI NIH HHS/United States
- P30 CA056036/CA/NCI NIH HHS/United States
- R01-CA-80250/CA/NCI NIH HHS/United States
- P30-CA-56036/CA/NCI NIH HHS/United States
- R01-CA-107382/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials